menu
    • menu

    Company profile for Tagoor Laboratories

    Tagoor Laboratories-PSE
    News
    Tagoor Labs gets DCGI approval for Favipiravir production

    05 Oct 2020

    // BIOSPECTRUMASIA

    Kunwar Khurana elevated to Head – Sales and Marketing

    09 Jun 2026

    // INDPHARMAPOST

    Roche Invests $3B In Nurix's Blood Cancer Protein Degrader

    09 Jun 2026

    // GLOBENEWSWIRE

    DATA COMPILATION
    #PharmaFlow

    Tagoor Laboratories

    Contact Supplier

    Website

    CPhI Milan

    Booth #4C108

    Book a meeting

    envelop Contact Supplier

    Latest Content by PharmaCompass

    https://www.youtube.com/embed/SbBRvRoS9q0?si=e77EdCpphYwbnWAy

    EVENTS

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    INTERMEDIATES

    Key Products KEY PRODUCTS

    INSPECTIONS & REGISTRATIONS

    PharmaCompass

    Tagoor's product development expertise, backed by our comprehensive understanding of the processes, helps us offer high-quality APIs.

    Related CompaniesRelated Companies

    About

    Tagoor Laboratories, established in 2018 and part of the Tagoor Group, provides APIs, advanced intermediates, and key starting materials for critical and high-growth therapeutic areas. The company emphasizes affordability, quality, and timely delivery, and also offers end-to-end CDMO services. Headquartered in Hyderabad, Tagoor Labs serves branded and generic pharmaceutical companies worldwide, with integrated functions covering R&D, manufacturing, quality, regulatory affairs, supply chain, marketing, and warehousing. Note: Product(s) under patent(s) are offered only for R&D purposes as per the Patent Act & not for commercial sale.

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Tagoor Laboratoriesindia-flag Flag
    Country
    Country
    India
    Address
    Address
    Plot No.: 75, H.No.: 1 – 98/3, First and Second Floors, Jubilee Enclave, Hit...
    Telephone
    Telephone
    +91 4029554530​
    Client Email
    Email
    krishnaveni.annapareddy@tagoorlabs.com
    Client Website
    Website
    http://www.tagoorlabs.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/tagoor-laboratories-pvt.-ltd/
    youtube
    YouTube
    http://www.youtube.com/@TagoorLabs
    Twitter
    Twitter
    Contact Info
    Others

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    CPhI Milan

    Booth #4C108

    envelop Contact Supplier

    CPhI Milan

    Contact Supplier

    Meeting

    Digital content read-more

    Explore the latest content creation from this company

    CORPORATE CONTENT #SupplierSpotlight

    Product List 2025

    read-more

      https://www.pharmacompass.com/pdf/party/content/tagoor-laboratories-party-content-27439.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    Corporate Presentation

    read-more

      https://www.pharmacompass.com/pdf/party/content/tagoor-laboratories-party-content-47181.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    API Product List 2025

    read-more

      https://www.pharmacompass.com/pdf/party/content/tagoor-laboratories-party-content-88525.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    Intermediates Product List 2025

    read-more

      https://www.pharmacompass.com/pdf/party/content/tagoor-laboratories-party-content-56222.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    Piperidine & Piperidone Derivatives 2025

    read-more

      https://www.pharmacompass.com/pdf/party/content/tagoor-laboratories-party-content-22056.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    Products Under Development 2025

    read-more

      https://www.pharmacompass.com/pdf/party/content/tagoor-laboratories-party-content-11209.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    DATA COMPILATION #PharmaFlow

    read-more
    read-more
    CEP Q1 2026 Update: CEP 2.0, EDQM’s new guidelines strengthen ecosystem; Indian firms top list of CEPs issued

    CEP Q1 2026 Update: CEP 2.0, EDQM’s new guidelines strengthen ecosystem; Indian firms top list of CEPs issued

    PharmaCompass is introducing a new regulatory update that tracks developments in Certificates of Suitability to the Monographs of the European Pharmacopoeia, referred to as CEPs. These certificates are a critical regulatory instrument in the global pharmaceutical supply chain.Also known as a Certification of Suitability (COS), CEPs are issued by the European Directorate for the Quality of Medicines and HealthCare (EDQM), with or without inspection of the manufacturing site. A CEP must be renewed every five years from its original issue date to remain valid, regardless of any revisions made during the interim period. However, a CEP does not replace Good Manufacturing Practice certification.CEPs are recognized as a trusted reference for API quality, thereby simplifying global registration strategies. Apart from Europe, the CEP system is widely used by many regulatory authorities, including those in Canada, Australia, Brazil, Singapore and South Africa. View CEPs Issued in Q1 2026 (Power BI Dashboard, Free Excel Available)CEP 2.0 enhances regulatory clarity, brings efficiency, global interoperability There are several types of CEPs, depending on the nature of the substance and evaluation. The most common type is the Chemical CEP, which confirms that a chemically synthesized API meets standards for purity and impurity control. Then there are Herbal CEPs for herbal substances and preparations.Another key category is the TSE CEP, which addresses risks associated with transmissible spongiform encephalopathies in animal-derived materials. In addition, there are Combined CEPs that may cover multiple aspects, such as chemical quality, TSE risk, and sterility. However, biological products such as vaccines and blood products fall outside the scope of the CEP framework.In 2023, the CEP system underwent a major transformation with the introduction of CEP 2.0, which marks a shift from a largely document-based system to a more structured, transparent, and digitally aligned model. This makes it easier for companies to manage compliance while improving trust among global regulators.While increasing data and compliance requirements for API manufacturers, CEP 2.0 enables better regulatory clarity, streamlined dossier integration, and stronger global acceptance. Overall, CEP 2.0 is designed to enhance regulatory clarity while making the system more efficient and globally interoperable. View CEPs Issued in Q1 2026 (Power BI Dashboard, Free Excel Available)Indian firms issued maximum CEPs; Sun Pharma and its subsidiaries, Jubilant Biosys top listIndia topped the charts for CEPs issued, both in terms of new CEPs and revisions in the first quarter (Q1) of 2026. Indian companies were issued 81 new CEPs in Q1 2026 (as against 40 in Q1 2025) and 203 revisions (as against 129 in Q1 2025). In comparison, Chinese companies were issued 42 new CEPs in Q1 2026 (against 25 in Q1 2025) and 53 revisions (against 67 in Q1 2025). Italy came a distant third, followed by Germany and Spain.India’s Sun Pharmaceuticals and its subsidiaries topped the list of companies with the maximum number of CEPs issued— while no new CEP was issued, 27 CEPs were revised in Q1 2026. At second place was Jubilant Biosys — 21 CEPs were revised in Q1 2026.In terms of products, the maximum CEPs were issued for amlodipine besylate (a calcium channel blocker used for treating hypertension), followed by sitagliptin phosphate (a type 2 diabetes medicine) and pregabalin (a drug used to treat neuropathic pain, fibromyalgia, seizures, and generalized anxiety disorder). Both amlodipine besylate and sitagliptin phosphate had not been issued new CEPs or revisions in Q1 2025. View CEPs Issued in Q1 2026 (Power BI Dashboard, Free Excel Available)EDQM introduces new guidelines to accelerate CEP assessments The EDQM charges fees for various services related to CEPs that depend on the type of request or regulatory activity involved. In general, fees apply to handling CEP applications, revisions or renewals and for offering technical advice (where applicants seek scientific or regulatory guidance).In March 2026, the EDQM introduced two new guidelines aimed at accelerating CEP assessments. The first is a reliance-based assessment pathway, which allows regulators to leverage prior approvals from trusted authorities, such as those in the EU, UK, Australia, Canada, and the WHO pre-qualification program. The second is a fast-track assessment route designed to expedite reviews in situations such as medicine shortages and to support initiatives like the EU Critical Medicines Act.Timelines have been significantly compressed under these new pathways. Initial evaluations are completed within 46 working days, compared to up to 115 days under the standard procedure. Applicants are given 30 calendar days to respond to queries, after which regulators complete the final assessment within 23 working days.Another important regulatory update relates to electronic submissions. From April 1, 2026, the EDQM will reject non-compliant CEP applications at the point of submission. All applications must include a validated electronic Common Technical Document (eCTD) dossier along with a proper validation report, submitted in line with the updated Common European Submission Portal (CESP) guidelines. Taken together, these developments signal a more rigorous yet efficient CEP ecosystem. View CEPs Issued in Q1 2026 (Power BI Dashboard, Free Excel Available)Our viewThe shift to CEP 2.0 signals a move toward greater transparency, digitalization, and global regulatory alignment. Though enhanced disclosure and stricter e-submission requirements may increase the compliance burden, especially for smaller manufacturers, the long-term gains are expected to be significant. Going forward, companies that invest in data quality and regulatory readiness stand to gain from these changes.
    subscribeSubscribe
    ExcelExcel Download

    Impressions: 2590

    https://www.pharmacompass.com/radio-compass-blog/cep-q1-2026-update-cep-2-0-edqm-s-new-guidelines-strengthen-ecosystem-indian-firms-top-list-of-ceps-issued

    #PharmaFlow by PHARMACOMPASS
    09 Apr 2026
    Share Share

    NEWS #PharmaBuzz

    read-more
    read-more
    Tagoor Labs gets DCGI approval for Favipiravir production
    Tagoor Labs gets DCGI approval for Favipiravir production

    05 Oct 2020

    // BIOSPECTRUMASIA

    https://www.biospectrumindia.com/news/60/17323/tagoor-labs-gets-dcgi-approval-for-favipiravir-production.html

    BIOSPECTRUMASIA
    05 Oct 2020
    Share Share

    KEY PRODUCTS

    read-more
    read-more

    TOP RANKED SUPPLIER FOR:

    Sponsored Ads.
    full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view

    Inspections and registrations

    Check the inspections & registration from this company

    ABOUT THIS PAGE

    Contact Tagoor Laboratories and get a quotation

    Tagoor Laboratories is a supplier offers 47 products (APIs, Excipients or Intermediates).

    Find Alpha Lipoic Acid bulk with CEP, WC offered by Tagoor Laboratories

    Find Loratadine bulk with CEP, WC offered by Tagoor Laboratories

    Find Pantoprazole Sodium bulk with CEP, WC offered by Tagoor Laboratories

    Find Alpha Lipoic Acid bulk with WC offered by Tagoor Laboratories

    Find Desloratadine bulk with WC offered by Tagoor Laboratories

    Find Domperidone bulk with WC offered by Tagoor Laboratories

    Find Domperidone Maleate bulk with WC offered by Tagoor Laboratories

    Find Esomeprazole Magnesium bulk with WC offered by Tagoor Laboratories

    Find Hydroxychloroquine Sulphate bulk with WC offered by Tagoor Laboratories

    Find Loratadine bulk with WC offered by Tagoor Laboratories

    Find Losartan Potassium bulk with WC offered by Tagoor Laboratories

    Find Molnupiravir bulk with WC offered by Tagoor Laboratories

    Find Pantoprazole Sodium bulk with WC offered by Tagoor Laboratories

    Find Rupatadine Fumarate bulk with CEP offered by Tagoor Laboratories

    Find Terbinafine Hydrochloride bulk with WC offered by Tagoor Laboratories

    Find Abiraterone Acetate bulk offered by Tagoor Laboratories

    Find Amitriptyline Hydrochloride bulk offered by Tagoor Laboratories

    Find Amlodipine Besylate bulk offered by Tagoor Laboratories

    Find Bilastine bulk offered by Tagoor Laboratories

    Find Cabozantinib bulk offered by Tagoor Laboratories

    Find Cyclobenzaprine bulk offered by Tagoor Laboratories

    Find Cyproheptadine Hydrochloride bulk offered by Tagoor Laboratories

    Find Dexlansoprazole bulk offered by Tagoor Laboratories

    Find Duloxetine Hydrochloride bulk offered by Tagoor Laboratories

    Find Favipiravir bulk offered by Tagoor Laboratories

    Find Fenofibrate bulk offered by Tagoor Laboratories

    Find Fexofenadine Hydrochloride bulk offered by Tagoor Laboratories

    Find Haloperidol bulk offered by Tagoor Laboratories

    Find Ibrutinib bulk offered by Tagoor Laboratories

    Find Imatinib Mesylate bulk offered by Tagoor Laboratories

    Find Ivabradine Hydrochloride bulk offered by Tagoor Laboratories

    Find Loperamide Hydrochloride bulk offered by Tagoor Laboratories

    Find Mavacamten bulk offered by Tagoor Laboratories

    Find Mirogabalin Besylate bulk offered by Tagoor Laboratories

    Find Montelukast Sodium bulk offered by Tagoor Laboratories

    Find Nortriptyline bulk offered by Tagoor Laboratories

    Find Omeprazole Magnesium bulk offered by Tagoor Laboratories

    Find Omeprazole Sodium bulk offered by Tagoor Laboratories

    Find Pazopanib Hydrochloride bulk offered by Tagoor Laboratories

    Find Rabeprazole Sodium bulk offered by Tagoor Laboratories

    Find Resmetirom bulk offered by Tagoor Laboratories

    Find Rimegepant Sulfate bulk offered by Tagoor Laboratories

    Find Ruxolitinib Phosphate bulk offered by Tagoor Laboratories

    Find Tegoprazan bulk offered by Tagoor Laboratories

    Find Tofacitinib Citrate bulk offered by Tagoor Laboratories

    Find Vildagliptin bulk offered by Tagoor Laboratories

    Find Vonoprazan Fumarate bulk offered by Tagoor Laboratories

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search